These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19181784)

  • 1. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.
    Iwanaga E; Nanri T; Matsuno N; Kawakita T; Mitsuya H; Asou N
    Haematologica; 2009 Mar; 94(3):433-5. PubMed ID: 19181784
    [No Abstract]   [Full Text] [Related]  

  • 2. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
    Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extramedullary tumors presenting double vision in patients with t(8;21)(q22;q22) acute myeloid leukemia lacking mutations in the receptor tyrosine kinase genes KIT or FLT3.
    Tsuji T; Takatsu N; Nosaka K; Kawakita T; Nanri T; Horikawa K; Mitsuya H; Asou N
    Leuk Res; 2010 Dec; 34(12):e320-2. PubMed ID: 20701971
    [No Abstract]   [Full Text] [Related]  

  • 4. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
    Li WY; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis.
    Parihar M; Kumar JA; Sitaram U; Balasubramanian P; Abraham A; Viswabandya A; George B; Mathews V; Srivastava A; Srivastava VM
    Leuk Lymphoma; 2012 Jan; 53(1):103-9. PubMed ID: 21745004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
    Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
    Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML with t(8;21) and trisomy 4: possible involvement of c-kit?
    Langabeer SE; Beghini A; Larizza L
    Leukemia; 2003 Sep; 17(9):1915; author reply 1915-6. PubMed ID: 12970800
    [No Abstract]   [Full Text] [Related]  

  • 8. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
    Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
    Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
    Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
    Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21)].
    Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):866-9. PubMed ID: 19698218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.
    Shimada A; Taki T; Tabuchi K; Tawa A; Horibe K; Tsuchida M; Hanada R; Tsukimoto I; Hayashi Y
    Blood; 2006 Mar; 107(5):1806-9. PubMed ID: 16291592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
    Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
    Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
    Larizza L; Magnani I; Beghini A
    Leuk Lymphoma; 2005 Feb; 46(2):247-55. PubMed ID: 15621809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
    Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
    Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
    Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
    Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A complex karyotype masked a cryptic variant t(8;21)(q22;q22) in a child with acute myeloid leukemia.
    De Figueiredo AF; Liehr T; Bhatt S; Binato R; De Souza MT; De Matos RR; Salles Tde J; Jordy FC; Ribeiro RC; Abdelhay E; Silva ML
    Leuk Lymphoma; 2011 Aug; 52(8):1593-6. PubMed ID: 21657952
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical and laboratory study of a complex translocation t (6; 21; 8) (p22; q22; q22) in two patients with acute myeloid leukemia].
    Gong JY; Liu XP; Li CW; Zhao XC; Dai Y; Qin S; Xiao JG; Huang Q; Xu FY; Wang F; Cui W; Liu SH; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):314-7. PubMed ID: 16875580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. t(8;21) (q22;q22) acute myelogenous leukemia in Mexico: a single institution experience.
    Ruiz-Argüelles GJ; Morales-Toquero A; Manzano C; Ruiz-Delgado GJ; Jaramillo P; Gonzalez-Carrillo ML; Reyes-Núñez V
    Hematology; 2006 Aug; 11(4):235-8. PubMed ID: 17178661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
    Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
    Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.